Видно, что за последние три года до

Видно, что за последние три года доля ММКИ III фазы возросла по сравнению с предыдущими годами. Доля исследований остальных фаз, наоборот, уменьшилась.
Остается лишь добавить, что из восьми разрешенных в 2013 г. международных исследований I фазы три приходятся на исследования препаратов для лечения онкологических заболеваний, по два – для лечения ревматоидного и идиопатического артритов и одно – препарата, планирующегося для терапии системной красной волчанки.

Результаты (английский) 1:

You can see that over the past three years, the proportion of ILYICH STEEL phase III has increased in comparison with previous years. The proportion of the remaining phases of the studies, by contrast, has gone down.
it only remains to add that of the eight allowed in the 2013 g. International Studies (I) phase three fall studies of drugs for the treatment of cancer, two each for rheumatoid and idiopathic arthritis drug, and one planned for the therapy of Systemic Lupus Erythematosus.

Результаты (английский) 2:

It can be seen that over the past three years the share IMCTs phase III increased compared with previous years. The share of the other phases of research, on the contrary, decreased.
remains only to add that of the eight approved in 2013, the international phase I studies three fall study drugs for the treatment of cancer, two - for the treatment of rheumatoid arthritis and idiopathic and one - preparation, plan for the treatment of systemic lupus erythematosus.

Результаты (английский) 3:

Can be seen that, in the past three years, the proportion of ММКИ phase III has increased compared to previous years. The proportion of исследований remaining phases, on the contrary, declined.
It only remains to add that, of the eight allowed in 2013.International исследований I phase three fall on the study drugs for the treatment of oncological заболеваний, two - for the treatment and some idiopathic arthritis and one drug,Klaus Kleinfeld identified for treatment системной красной arthritis.